SCHEDULE: Affinity Asset Advisors Discloses 5.7% Stake in Avalo Therapeutics

Affinity Asset Advisors and Michael Cho have disclosed a 5.7% beneficial ownership stake in Avalo Therapeutics, Inc. through a Schedule 13G filing.

Summary

• Affinity Asset Advisors, LLC and Michael Cho (collectively, "Reporting Persons") beneficially own 1,051,054 shares of Avalo Therapeutics, Inc. Common Stock.
• This represents approximately 5.7% of the Issuer's Common Stock outstanding.
• The percentage is based on 18,512,757 shares outstanding as of December 31, 2025, as reported in Avalo Therapeutics' Form S-3 filed on January 8, 2026.
• Affinity Asset Advisors, LLC, as the investment manager of Affinity Healthcare Fund, LP, exercises voting and investment power over these securities.
• Michael Cho, the managing member of Affinity Asset Advisors, LLC, is also deemed a beneficial owner.
• The Reporting Persons hold sole voting and sole dispositive power over all 1,051,054 shares as of the filing date.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake suggests investor confidence in Avalo Therapeutics, though the filing itself is purely a disclosure of ownership and not an operational update.

Positives

• A significant institutional investor, Affinity Asset Advisors, LLC, and its managing member, Michael Cho, have taken a substantial 5.7% stake in Avalo Therapeutics, potentially signaling confidence in the company's future.
• The shift from shared to sole voting and dispositive power for the Reporting Persons indicates a consolidated control over their investment in Avalo Therapeutics.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Avalo Therapeutics, Inc. or the Reporting Persons regarding the company's future performance or strategic direction, beyond the standard certification that the shares were acquired in the ordinary course of business and not for control purposes.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that a 5.7% stake by an investment advisor like Affinity Asset Advisors in a biotechnology company such as Avalo Therapeutics can be viewed as a vote of confidence, particularly given the often volatile and capital-intensive nature of the biotech sector. Such an investment suggests that the fund sees potential value in Avalo's pipeline or strategic direction, even if the filing explicitly states the investment is not for control purposes. This level of ownership could also provide a stable shareholder base for the company.

Comparison to Industry Standards

• StockSavvy.ai observes that a 5.7% passive stake is a common entry point for institutional investors seeking exposure to specific sectors or companies without immediately pursuing activist roles.
• For instance, similar stakes are often seen in smaller-cap biotech firms where institutional backing can be crucial. While not directly comparable to major pharmaceutical giants like Pfizer or Johnson & Johnson, where such a percentage would represent a much larger absolute investment, for a company of Avalo Therapeutics' likely market capitalization, this is a meaningful position.
• Other specialized healthcare funds often take similar positions in emerging biotech companies like those developing novel therapies, such as a 5% stake by Baker Bros. Advisors in a clinical-stage oncology company or a 6% stake by Perceptive Advisors in a rare disease therapeutics firm, indicating a belief in long-term growth potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 5.7% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: The presence of a substantial institutional shareholder may lead to increased scrutiny or engagement, even if the stake is declared passive.

Key Dates

Recommendation

The filing indicates a significant institutional stake in Avalo Therapeutics, which is generally a positive signal of investor confidence. However, as a Schedule 13G, it provides no operational or financial performance updates. Without further information on the company's fundamentals, pipeline progress, or strategic direction, a 'hold' recommendation is prudent, acknowledging the positive signal while awaiting more comprehensive data for a stronger conviction.

Keywords

Avalo Therapeutics, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Management